Becton, Dickinson and Company reported third quarter fiscal 2025 revenues of $5.5 billion, reflecting a 10.4% increase compared to the prior year, with organic growth at 3.0%. Both GAAP and adjusted diluted earnings per share (EPS) rose to $2.00 and $3.68, respectively. The company also reported improvements in gross margin and operating income, with GAAP margins increasing by 160 basis points and operating income up by 46.6%. Additionally, Becton Dickinson raised its full-year adjusted EPS guidance to a range of $14.30 to $14.45, indicating a growth of 9.4% at the midpoint.
The company announced a definitive agreement to combine its Biosciences and Diagnostic Solutions business with Waters Corporation, aimed at creating a leader in life sciences and diagnostics. Becton Dickinson plans to invest $35 million in its Nebraska facility to enhance production capabilities for its PosiFlush™ Prefilled Flush Syringe. The report highlighted various business unit performances, including strong growth in Medication Delivery Solutions and double-digit growth in the Interventional segment. The company also submitted an FDA application for a new at-home HPV test and received clearance for a rapid COVID-19 test.
linkAug 07, 2025 06:33:15
Becton Dickinson and Company has entered into definitive agreements with Waters Corporation to combine its Biosciences and Diagnostic Solutions business with Waters in a Reverse Morris Trust transaction. As part of this deal, Becton Dickinson will receive approximately $4 billion in cash, and its shareholders will own 39.2% of the outstanding Waters common stock after the transaction is completed. The transaction has received unanimous approval from the Boards of Directors of both companies and involves a series of agreements to facilitate the separation and merger processes.
The transaction is contingent upon various conditions, including regulatory approvals and the satisfaction of closing conditions outlined in the agreements. The Merger Agreement stipulates that following the spin-off, the newly formed entity will merge with Waters, with shareholders of SpinCo receiving shares of Waters common stock. The agreement also includes provisions for adjusting the exchange ratio to meet tax requirements and outlines the governance structure of the new combined entity. A termination fee of $733 million is specified should the merger not be completed under certain circumstances.
linkJul 14, 2025 17:05:59
Becton, Dickinson and Company (BD) and Waters Corporation have entered into definitive agreements to combine BD's Biosciences and Diagnostic Solutions business with Waters in a Reverse Morris Trust transaction valued at approximately $17.5 billion. This merger is expected to create a leading life science and diagnostics company, enhancing both firms' market reach and operational capabilities. BD shareholders will own about 39.2% of the combined entity, while Waters shareholders will hold approximately 60.8%. BD is set to receive a cash distribution of around $4 billion as part of the transaction.
The merger has been unanimously approved by the boards of both companies and is anticipated to close by the end of the first quarter of 2026, pending regulatory approvals and other customary conditions. Udit Batra, current CEO of Waters, will lead the new company, which will continue to operate under the Waters name. BD's Biosciences and Diagnostic Solutions business is projected to generate approximately $3.4 billion in revenue and $925 million in adjusted EBITDA for the year 2025, indicating a significant contribution to the combined entity's financial performance.
linkJul 14, 2025 06:20:51
Becton, Dickinson and Company has reached a proposed settlement in a stockholder derivative litigation involving allegations against certain individual defendants for breaches of fiduciary duties. If approved by the court, the settlement would resolve all claims related to the Consolidated Federal Derivative Action and dismiss the case with prejudice, meaning current stockholders will be barred from contesting the settlement or pursuing related claims in the future. A Settlement Hearing is scheduled for August 11, 2025, to determine the fairness of the settlement terms.
The litigation stems from claims that the defendants made false statements regarding software defects in the Alaris infusion pump system, which allegedly inflated the company's stock price and resulted in legal liabilities. The proposed settlement includes a monetary component funded by the company’s directors' and officers' insurance, along with certain corporate governance modifications. The court has not made any findings regarding the merits of the case, and current stockholders have the right to object to the settlement before the hearing date.
linkJun 16, 2025 16:32:00
BD reported a fourth quarter revenue of $5.4 billion, marking a 6.9% increase from the previous year, with notable growth in GAAP and adjusted diluted earnings per share (EPS) of $1.45 and $3.81, respectively. The company also highlighted a significant rise in cash flow from continuing operations, which grew by 28.5% to $3.8 billion, and free cash flow, which increased by 47.4% to $3.1 billion. The acquisition of Edwards Lifesciences' Critical Care product group was mentioned as a strategic move to enhance their portfolio in high-growth areas, alongside various product launches and approvals in BD Life Sciences and BD Medical segments. Additionally, BD was recognized for its workplace inclusivity and corporate citizenship efforts.
On the downside, the company faced challenges in the BD Life Sciences segment due to lower market demand for research instruments, which was partially offset by growth in clinical solutions. There were also expected declines in revenues from China and certain market dynamics affecting the Biosciences and Pharmaceutical sectors. The Medication Management Solutions experienced a decline in Dispensing Solutions compared to the prior year, and the performance in the Interventional segment was impacted by a tough comparison from the previous year in Advanced Repair & Reconstruction. Overall, while BD showed strong financial results, it also navigated some market pressures and challenges in specific segments.
linkNov 07, 2024 06:37:15
BD has successfully reached an agreement to settle most of its hernia litigation, aiming to reduce uncertainty for all involved parties. The settlement amount is covered by the company's existing reserves and will be disbursed over several years, ensuring that it does not impact BD's financial goals or capital strategies. Importantly, the company maintains its stance of no admission of liability or wrongdoing, continuing to defend itself in unresolved cases while prioritizing patient safety and product quality.
This resolution addresses a significant portion of BD's product litigation reserve, which is a positive step for the company as it allows for better financial planning and stability. The structured payment plan was anticipated as part of BD's cash flow management, indicating that the company is taking proactive measures to handle its litigation challenges without adverse effects on its overall financial health.
linkOct 02, 2024 17:03:34
BD announced strong financial results for Q3 2024, with revenue reaching $5.0 billion and significant growth in earnings per share. Cash flow from operations surged by 60%, indicating solid financial health. The company raised its revenue and earnings guidance for the fiscal year, reflecting confidence in continued growth. CEO Tom Polen highlighted the positive transformation of BD into a leading medical technology company.
linkAug 01, 2024 06:32:40
Dave Hickey, BD's executive vice president, plans to retire on July 1 after a decade at the company. Hickey led BD's efforts during the COVID-19 pandemic to develop rapid diagnostic tests. BD will appoint a successor before his retirement. Hickey expressed pride in the company's accomplishments and its impact on global healthcare. BD, with over 70,000 employees worldwide, focuses on improving medical technology and enhancing patient care globally.
linkFeb 27, 2024 06:54:50